Equillium, Inc. Overview
Pro stress-test →Equillium is a clinical-stage biotechnology company developing therapeutics to treat severe autoimmune and inflammatory disorders with unmet medical need. The company focuses on immunobiology-driven approaches with a lead candidate positioned to enter Phase 1 studies in mid-2026, aiming to establish clinical proof-of-concept in previously untreated therapeutic areas.
Strategic Profile
Pro stress-test →The lead program, EQ504, is an aryl hydrocarbon receptor (AhR) modulator designed with a non-immunosuppressive mechanism of action that maintains barrier function and promotes tissue repair while regulating resident immune cells. Recent $50M financing extends cash runway through 2027, positioning the company to advance EQ504 and validate its differentiated immunology platform in multiple indications.
Competitive Landscape
Pro stress-test →Equillium competes in the crowded immunomodulation space against larger, better-capitalized competitors developing JAK inhibitors, anti-TNF biologics, and other inflammation modulators. Differentiation rests on AhR-based mechanism and non-immunosuppressive approach for barrier organ diseases, a relatively underpenetrated niche within severe immune-inflammatory disorders.
Industry Context
Equillium, Inc. operates in Biotechnology - Clinical-Stage Immunology/Inflammation.
Key facts
Founded: 2017 · Headquarters: La Jolla, California